Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

A New Transmission Blocking Vaccine for Leishmania Infection

Posted Mar 16 2010 5:00pm

Description of Invention:
A novel transmission blocking vaccine has been developed that can eliminate or reduce the number of Leishmania chagasi parasites in the gut of the sand fly species, Lutzomyia longipalpis. The vaccine involves the production of antibodies to the sand fly midgut protein, LP1, which is normally expressed in the midgut of the sand fly during a blood meal. This vaccine could potentially block parasite transmission from the sand fly to mammalian hosts and significantly reduce the incidence of leishmaniasis in endemic areas of the world such as Brazil, India, and Indonesia where leishmaniasis accounts for over 58,000 deaths annually.

Studies have shown that LP1 antibodies produced by immunized mice are able to reduce the number of L. chagasi parasites that develop in the midgut of Lu. longipalpis. These results illustrate the potential use of the protein as a vaccine to immunize dogs and protect humans from visceral leishmaniasis transmitted by the sand flies that feed on the infected, vaccinated dogs. In endemic areas such as Brazil where dogs are the principal reservoir for L. chagasi, the LPl antigen alone or in combination with other sand fly midgut proteins could be used to immunize household pets and stray dogs. Vaccinated dogs will produce antibodies to LPl, and once a sand fly feeds on blood from the infected and vaccinated dogs, the antibodies will inhibit development of the parasite in the gut of the sand fly. This approach can effectively block Leishmania transmission to human hosts. Such vaccines have the potential to reduce the risk of humans acquiring leishmaniasis without the risks involved in human vaccination.

Applications:
  • Transmission blocking vaccine for Leishmania infection
  • Vaccination of dogs as reservoirs for the Leishmania parasite


Development Status:
Early stage

Inventors:
Ryan C Jochim (NIAID)
Jesus G Valenzuela (NIAID)


Patent Status:
HHS, Reference No. E-305-2009/0
US, Application No. 61/256,250 filed 29 Oct 2009


Relevant Publication:
  1. Jochim RC, Teixeira CR, Laughinghouse A, Mu J, Oliveira F, Gomes RB, Elnaiem DE, Valenzuela JG. The midgut transcriptome of Lutzomyia longipalpis: comparative analysis of cDNA libraries from sugar-fed, blood-fed, post-digested and Leishmania infantum chagasi-infected sand flies. BMC Genomics. 2008 Jan 14;9(1):15. [ PubMed: 18194529 ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The NIAID, OTD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize "A New Transmission Blocking Vaccine for Leishmania Infection". Please contact Dana Hsu at 301-496-2400 for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Vaccines
Infectious Diseases - Other
Rare Diseases
Neglected Diseases



For Additional Information Please Contact:
John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: js852e@nih.gov
Phone: 301-435-5236
Fax: 301-402-0220


Ref No: 2086

Updated: 03/2010

Post a comment
Write a comment:

Related Searches